What is Pfizer going to buy next? Albert Bourla outlines his M&A strategy in the post-Upjohn era
In a call with analysts on Monday, CEO Albert Bourla put the spotlight on the big pharma’s shift to becoming a “smaller, more focused, science-based company with a singular focus on innovative pharma” now that Upjohn has been dealt with and he has a consumer deal with GSK.
In the Bourla era, that means a steady flow of new deals, but nothing that tips the big pharma scale.
That approach has already triggered deals for Therachon (small, with $340 million cash upfront) and Array (mid-sized at $11.4 billion), and Bourla says the BD team continues to scout for “bolt-on opportunities, that would be on early to mid-stage opportunities, where maybe there is higher risk as you know, but the value creation is further greater. And the risk of operational disruption is perhaps lower.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.